Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;108(2 Pt 2):E66-70.
doi: 10.1111/j.1464-410X.2010.09819.x. Epub 2010 Nov 10.

Modulation of smooth muscle tonus in the lower urinary tract: interplay of myosin light-chain kinase (MLCK) and MLC phosphatase (MLCP)

Guiting Lin  1 , Thomas M Fandel, Alan W Shindel, Guifang Wang, Lia Banie, Hongxiu Ning, Tom F Lue, Ching-Shwun Lin
Affiliations

Modulation of smooth muscle tonus in the lower urinary tract: interplay of myosin light-chain kinase (MLCK) and MLC phosphatase (MLCP)

Guiting Lin et al. BJU Int. 2011 Jul.

Abstract

Objective: To assess and compare the expression and activity of myosin light-chain kinase (MLCK) and MLC phosphatase (MLCP) in rat bladder and urethra.

Materials and methods: Bladder and urethral smooth muscles were obtained from 2-month-old female Sprague-Dawley rats. They were analysed by real-time polymerase chain reaction for the mRNA expression of MLCK and myosin phosphatase-targeting subunit of protein phosphatase type 1 (MYPT1, a subunit of MLCP). Levels of MLCK and MYPT1 mRNA expression were determined as a ratio to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The tissues were also analysed by Western blotting for MLCK and MYPT1 protein expression as a ratio to the expression of β-actin. A two-step enzymatic activity assay using phosphorylated and dephosphorylated smooth muscle myosin was used to assess MLCK and MLCP activity.

Results: MLCK mRNA expression was higher in the bladder than in the urethra [mean (sd) ratio to GAPDH: 0.26 (0.17) vs 0.14 (0.12); P = 0.09]. MYPT1 mRNA expression was significantly higher in the bladder than in the urethra [mean (sd) ratio to GAPDH: 2.31 (1.04) vs 0.56 (0.36); P = 0.001]. Expression of both MLCK and MYPT1 protein was significantly higher in the bladder compared with the urethra [mean (sd) ratio to β-actin: 1.63 (0.25) vs 0.91 (0.29) and 0.97 (0.10) vs 0.37 (0.29), respectively; both P < 0.001]. Enzymatic assay identified significantly greater MLCK activity in the bladder than in the urethra. While, MLCP activity was lower in the bladder than in the urethra.

Conclusion: In healthy young female rats, MLCK activity is higher and MLCP activity is lower in the bladder relative to the urethra. These differences probably play a role in modulating the functional differences between bladder and urethral smooth muscle tone.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Rat bladder and urethra (n=6 each) were analyzed by real-time PCR for MLCK and MYPT1 mRNA expression. Expression level is relative to GAPDH expression and based on 3 independent experiments.
FIG. 2
FIG. 2
Rat bladder and urethra (n=6 each) were analyzed by western blot for MLCK and MYPT1 expression. A. Representative gel showing the MLCK, MYPT1, and β-Actin bands of 3 bladder and 3 urethra samples. B. Graph representation of the compiled densitometry data from A. Expression level is relative to β-Actin expression and based on 3 independent experiments.
FIG. 3
FIG. 3
Rat bladder and urethra (n=6 each) were analyzed for MLCK activity at 1, 3, and 5-min time points. MLCK activity was calculated as pMole of 32P bound to MLC20 per g of cell extract protein. * indicates p<0.01.
FIG. 4
FIG. 4
Rat bladder and urethra (n=6 each) were analyzed for MLCP activity at 1, 3, and 5-min time points. MLCP activity was calculated as pMole of 32P released from 32P-labled MLC20 per g of cell extract protein. * indicates p<0.05.
See this image and copyright information in PMC

References

    1. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev. 2004;56:581–631. - PubMed
    1. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol. 2006;147 Suppl 2:S25–S40. - PMC - PubMed
    1. Brading AF. The physiology of the mammalian urinary outflow tract. Exp Physiol. 1999;84:215–221. - PubMed
    1. Fleichman M, Schneider T, Fetscher C, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. II. Protein kinases. J Pharmacol Exp Ther. 2004;308:54–58. - PubMed
    1. Fry CH, Skennerton D, Wood D, Wu C. The cellular basis of contraction in human detrusor smooth muscle from patients with stable and unstable bladders. Urology. 2002;59:3–12. - PubMed

Publication types